Polyvalent immunoglobulins: Challenges and perspectives

Blood Transfusion

Volumn 11, Issue SUPPL. 4, 2013, Pages

  Quinti, Isabella ^a   Coluzzi, Serelina ^b   Pulvirenti, Federica ^a   Prezzo, Alessandro ^a   Girelli, Gabriella ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Adverse reactions; Biological activites; Intravenous immunoglobulins; Subcutaneous immunoglobulin; Treatment priorities

Indexed keywords

IMMUNOGLOBULIN;

ACUTE KIDNEY FAILURE; ADAPTIVE IMMUNITY; ADULT RESPIRATORY DISTRESS SYNDROME; ANAPHYLAXIS; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ASEPTIC MENINGITIS; CHILL; DIARRHEA; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; ERYTHEMA MULTIFORME; FATIGUE; FEVER; HEADACHE; HEART INFARCTION; HEMOLYSIS; HUMAN; HYPOTENSION; IMMUNOREGULATION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; INNATE IMMUNITY; ITALY; LIVER DYSFUNCTION; LOADING DRUG DOSE; MYALGIA; NAUSEA; RASH; REVIEW; RIGOR; STEVENS JOHNSON SYNDROME; TACHYCARDIA; THROMBOSIS; TRANSFUSION RELATED ACUTE LUNG INJURY; VOMITING;

HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS;

EID: 84885591494     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2013.008s     Document Type: Review

References (30)

1. th ed. (4.02). Strasbourg: Council of Europe Publishing; 2002.
2. Ochsenbein AF, Fehr T, Lutz C, et al. Control of early viral and bacterial distribution and disease by natural antibodies. Science 1999; 286: 2156-9. (Pubitemid 129516290)
3. Kaveri SV. Intravenous immunoglobulin: exploiting the potential of natural antibodies. Autoimmun Rev. 2012; 11: 792-4.
4. Durandy A, Kaveri SV, Kuijpers TW, et al. Intravenous immunoglobulins - understanding properties and mechanisms. Clin Exp Immunol 2009; 158 (Suppl 1): 2-13.
5. Kaveri SV, Lacroix-Desmazes S, Bayry J. The antiinflammatory IgG. N Engl J Med 2008; 359: 307-9.
6. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol. 2013; 13: 176-89
7. Tha-In T, Bayry J, Metselaar HJ, et al. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 2008; 29: 608-15.
8. Gelfand E. Intravenous Immune Globulin in Autoimmune and Inflammatory Diseases. N Engl J Med 2012; 367: 2015-25.
9. Kaveri KS, Maddur MS, Hegde P, et al. Immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin and Exp Immunol 2011; 164: 2-5.
10. Cunningham Rundles C. Key aspects for successful immunoglobulin therapy of primary immunodeficiencies. Clinical and Experimental Immunology. 2011; 164 (Suppl 2), 16-19
11. Ochs HD, Fischer SH, Wedgwood RJ. Comparison of highdose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases. Am J Med 1984; 76: 78-82. (Pubitemid 14126155)
12. Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol 2008; 122: 210-2. (Pubitemid 351899076)
13. Lucas M, Hugh-Jones K, Welby A, et al. Immunomodulatory therapy to achieve maximum efficacy: doses, monitoring, compliance, and self-infusion at home. J Clin Immunol 2010; 30: S84-9.
14. Roifman CM, Berger M, Notarangelo LD. Management of primary antibody deficiency with replacement therapy: summary of guidelines. Immunol Allergy Clin North Am 2008; 28: 875-6.
15. Chapel H, Lucas M, Lee M. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 2008; 112: 277-86.
16. Quinti I, Soresina A, Guerra A, et al; IPINet Investigators. Effectiveness of Immunoglobulin Replacement Therapy on Clinical Outcome in Patients with Primary Antibody Deficiencies: Results from a Multicenter Prospective Cohort Study. J Clin Immunol 2011; 31: 315-22.
17. Quinti I, Milito C, Pulvirenti F, et al. Better patient's outcome can be achieved by shortening the monthly replacement intervals in patients with severe primary antibody deficiencies and adverse reactions to immunoglobulins. J Biol Reg Homeos Ag 2013 (in press).
18. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol 2010; 137: 21-30.
19. Orange JS, Ochs HD, Cunningham-Rundles C. Prioritization of Evidence-Based Indications for Intravenous Immunoglobulin. J Clin Immunol 2013; 33: 1033-6.
20. Orange JS, Hossney EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006; 117 (Suppl): S525-53.
21. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315: 341-7. (Pubitemid 16060087)
22. Bayry J, Negi VS, Kaveri SV. Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol 2011; 7: 349-59.
23. Tha-In T, Bayry J, Metselaar HJ, et al. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 2008; 29: 608-15.
24. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008; 26: 51-33.
25. Seite JF, Shoenfeld Y, Youinou P, Hillion S. What is the contents of the magic draft IVIg? Autoimmun Rev 2008; 7: 435-9.
26. Kaveri SV, Lacroix-Desmazes S, Bayry J. The antiinflammatory IgG. N Engl J Med 2008; 359: 307-9.
27. Durandy A, Kaveri SV, Kuijpers TW, et al. Intravenous immunoglobulins - understanding properties and mechanisms. Clin Exp Immunol 2009; 158 (Suppl 1): 2-13.
28. Anthony RM, Ravetch JV. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol. 2010; 30 (Suppl 1): S9-14.
29. Baxley A, Akhtari M. Hematologic toxicities associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2011; 11: 1663-7.
30. Van der Heijden J, Geissler J, van Mirre E, et al. A novel splice variant of FcγRIIa: a risk factor for anaphylaxis in patients with hypogammaglobulinemia. J Allergy Clin Immunol 2013; 131: 1408-16.